指南与共识乳腺癌

PI3K/AKT/mTOR抑制剂治疗晚期乳腺癌临床应用专家共识

[Expert consensus on the clinical application of PI3K/AKT/mTOR inhibitors in the treatment of advanced breast cancer].
指南 / 共识 · Zhonghua Zhong Liu Za Zhi · 2022-01-01

该共识由专家小组制定,系统阐述PAM信号通路在乳腺癌中的作用、PI3K/AKT/mTOR抑制剂的疗效与临床应用、不良事件管理及PIK3CA基因检测建议。随机临床试验显示此类抑制剂对晚期乳腺癌尤其HR阳性/HER2阴性患者带来显著临床获益,Alpelisib和依维莫司已获FDA批准。

要点

  • PAM信号通路与晚期乳腺癌内分泌治疗耐药密切相关。
  • PI3K/AKT/mTOR抑制剂对HR阳性/HER2阴性晚期乳腺癌患者带来显著临床获益。
  • 共识涵盖疗效、临床应用、不良事件管理及PIK3CA基因检测建议。

核心结论

  • 专家共识旨在明确PAM信号通路抑制剂在乳腺癌中的作用、疗效、临床应用、不良事件管理及PIK3CA检测,以提高中国肿瘤医师认知并推进精准决策。

研究设计与样本

  • 由共识专家小组成员制定专家共识,系统介绍PAM信号通路机制、抑制剂疗效、临床应用、不良事件管理及PIK3CA基因检测建议。

主要发现

  • 随机临床试验证实PI3K/AKT/mTOR抑制剂为晚期乳腺癌患者尤其HR阳性/HER2阴性患者带来显著临床获益。
  • PI3K抑制剂Alpelisib和mTOR抑制剂依维莫司已获美国食品和药物管理局批准上市。
  • 依维莫司已在国家药品监督管理局获批乳腺癌新适应证,Alpelisib有望不久在中国上市。

临床怎么用

  • 共识系统介绍PAM信号通路抑制剂疗效、临床应用、不良事件管理及PIK3CA基因检测建议,供中国临床肿瘤医师参考。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT)/mammalian target of rapamycin (mTOR) signaling pathway (PAM pathway) plays an important role in the development of breast cancer and are closely associated with the resistance to endocrine therapy in advanced breast cancer. Therefore, anti-cancer treatment targeting key molecules in this signaling pathway has become research hot-spot in recent years. Randomized clinical trials have demonstrated that PI3K/AKT/mTOR inhibitors bring significant clinical benefit to patients with advanced breast cancer, especially to those with hormone receptor (HR)-positive, human epidermal growth factor receptor (HER) 2-negative advanced breast cancer. Alpelisib, a PI3K inhibitor, and everolimus, an mTOR inhibitor, have been approved by Food and Drug Administration. Based on their high efficacy and relatively good safety profile, expanded indication of everolimus in breast cancer have been approved by National Medical Products Administration. Alpelisib is expected to be approved in China in the near future. The members of the consensus expert panel reached this consensus to comprehensively define the role of PI3K/AKT/mTOR signaling pathway in breast cancer, efficacy and clinical applications of PI3K/AKT/mTOR inhibitors, management of adverse reactions, and PIK3CA mutation detection, in order to promote the understanding of PI3K/AKT/mTOR inhibitors for Chinese oncologists, improve clinical decision-making, and prolong the survival of target patient population. 磷脂酰肌醇3-激酶(PI3K)/蛋白激酶B(AKT)/哺乳动物雷帕霉素靶蛋白(mTOR)信号通路(PAM信号通路)在乳腺癌发生发展中发挥重要作用,与晚期乳腺癌内分泌治疗耐药密切相关,以PAM信号通路中的关键分子为靶点的抗癌治疗成为了近几年的研究热点。靶向PAM信号通路抑制剂为晚期乳腺癌患者尤其是激素受体阳性人表皮生长因子受体2阴性患者带来明显临床获益。目前,美国食品和药物管理局批准上市的PAM信号通路抑制剂包括PI3K抑制剂Alpelisib和mTOR抑制剂依维莫司,同时,依维莫司也在国内获得批准用于乳腺癌新适应证,Alpelisib有望不久在中国上市。鉴于此,专家制定了PAM信号通路抑制剂治疗晚期乳腺癌的临床应用专家共识,系统地介绍了PAM信号通路的机制、PAM信号通路抑制剂的疗效、临床应用、不良事件管理及PIK3CA基因检测建议,旨在提高中国临床肿瘤医师对PAM信号通路抑制剂的认知,推进临床决策的精准性,达到延长患者生存时间的目标。.

来源:Zhonghua Zhong Liu Za Zhi,查看原文。版权归原作者所有。

引用

  1. [Expert consensus on the clinical application of PI3K/AKT/mTOR inhibitors in the treatment of advanced breast cancer]. Zhonghua Zhong Liu Za Zhi. 2022. PMID: 35880333. doi:10.3760/cma.j.cn112152-20220412-00251

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。